South Korean PE fund invests in Montréal biopharmaceutical facility
Green Cross Biotherapeutics Inc, an affiliate of South Korean health solutions business Green Cross Corp, has begun construction of its biopharmaceutical facility located on the Montréal Technoparc's Saint-Laurent campus. The $315 million project will result in the first intravenous immunoglobulin and albumin manufacturing plant in Canada. The private equity fund of Korean National Pension Service has committed $70 million in project funding, while Investissement Québec has committed $25 million. The facility is expected to ready for full commercial operations in 2019.
2 June 2015•4 mins read
